Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol

R Franca, P Rebora, N Bertorello, F Fagioli, V Conter, A Biondi, A Colombini, C Micalizzi, M Zecca, R Parasole, F Petruzziello, G Basso, M C Putti, null Locatelli, P d'Adamo, M G Valsecchi, G Decorti, M Rabusin

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Drug-related toxicities represent an important clinical concern in chemotherapy, genetic variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was performed on 508 pediatric acute lymphoblastic leukemia patients treated with AIEOP-BFM 2000 protocol: 28 variants were genotyped by VeraCode and Taqman technologies, deletions of GST-M1 and GST-T1 by multiplex PCR. Toxicities were derived from a central database: 251 patients (49.4%) experienced at least one gastrointestinal (GI) or hepatic (HEP) or neurological (NEU) grade III/IV episode during the remission induction phase: GI occurred in 63 patients (12.4%); HEP in 204 (40.2%) and NEU in 44 (8.7%). Logistic regression model adjusted for sex, risk and treatment phase revealed that ITPA rs1127354 homozygous mutated patients showed an increased risk of severe GI and NEU. ABCC1 rs246240 and ADORA2A rs2236624 homozygous mutated genotypes were associated to NEU and HEP, respectively. These three variants could be putative predictive markers for chemotherapy-related toxicities in AIEOP-BFM protocols.
Original languageEnglish
Pages (from-to)4-10
Number of pages7
JournalPharmacogenomics Journal
Volume17
Issue number1
DOIs
Publication statusPublished - Jan 2017

Fingerprint

Pharmacogenetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Liver
Logistic Models
Therapeutics
Remission Induction
Drug Therapy
Multiplex Polymerase Chain Reaction
Drug-Related Side Effects and Adverse Reactions
Genotype
Databases
Pediatrics
Technology
PVDA protocol

Keywords

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols
  • Chemical and Drug Induced Liver Injury
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Consolidation Chemotherapy
  • Female
  • Gastrointestinal Diseases
  • Gene Deletion
  • Genetic Predisposition to Disease
  • Glutathione Transferase
  • Humans
  • Induction Chemotherapy
  • Infant
  • Logistic Models
  • Male
  • Multidrug Resistance-Associated Proteins
  • Multiplex Polymerase Chain Reaction
  • Mutation
  • Nervous System Diseases
  • Pharmacogenetics
  • Pharmacogenomic Testing
  • Pharmacogenomic Variants
  • Phenotype
  • Polymorphism, Single Nucleotide
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Predictive Value of Tests
  • Pyrophosphatases
  • Receptor, Adenosine A2A
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Journal Article

Cite this

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol. / Franca, R; Rebora, P; Bertorello, N; Fagioli, F; Conter, V; Biondi, A; Colombini, A; Micalizzi, C; Zecca, M; Parasole, R; Petruzziello, F; Basso, G; Putti, M C; Locatelli, null; d'Adamo, P; Valsecchi, M G; Decorti, G; Rabusin, M.

In: Pharmacogenomics Journal, Vol. 17, No. 1, 01.2017, p. 4-10.

Research output: Contribution to journalArticle

@article{4c952ae9c4484b24907934e37352c70a,
title = "Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol",
abstract = "Drug-related toxicities represent an important clinical concern in chemotherapy, genetic variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was performed on 508 pediatric acute lymphoblastic leukemia patients treated with AIEOP-BFM 2000 protocol: 28 variants were genotyped by VeraCode and Taqman technologies, deletions of GST-M1 and GST-T1 by multiplex PCR. Toxicities were derived from a central database: 251 patients (49.4{\%}) experienced at least one gastrointestinal (GI) or hepatic (HEP) or neurological (NEU) grade III/IV episode during the remission induction phase: GI occurred in 63 patients (12.4{\%}); HEP in 204 (40.2{\%}) and NEU in 44 (8.7{\%}). Logistic regression model adjusted for sex, risk and treatment phase revealed that ITPA rs1127354 homozygous mutated patients showed an increased risk of severe GI and NEU. ABCC1 rs246240 and ADORA2A rs2236624 homozygous mutated genotypes were associated to NEU and HEP, respectively. These three variants could be putative predictive markers for chemotherapy-related toxicities in AIEOP-BFM protocols.",
keywords = "Adolescent, Antineoplastic Combined Chemotherapy Protocols, Chemical and Drug Induced Liver Injury, Child, Child, Preschool, Clinical Trials as Topic, Consolidation Chemotherapy, Female, Gastrointestinal Diseases, Gene Deletion, Genetic Predisposition to Disease, Glutathione Transferase, Humans, Induction Chemotherapy, Infant, Logistic Models, Male, Multidrug Resistance-Associated Proteins, Multiplex Polymerase Chain Reaction, Mutation, Nervous System Diseases, Pharmacogenetics, Pharmacogenomic Testing, Pharmacogenomic Variants, Phenotype, Polymorphism, Single Nucleotide, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Predictive Value of Tests, Pyrophosphatases, Receptor, Adenosine A2A, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Journal Article",
author = "R Franca and P Rebora and N Bertorello and F Fagioli and V Conter and A Biondi and A Colombini and C Micalizzi and M Zecca and R Parasole and F Petruzziello and G Basso and Putti, {M C} and null Locatelli and P d'Adamo and Valsecchi, {M G} and G Decorti and M Rabusin",
year = "2017",
month = "1",
doi = "10.1038/tpj.2015.83",
language = "English",
volume = "17",
pages = "4--10",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol

AU - Franca, R

AU - Rebora, P

AU - Bertorello, N

AU - Fagioli, F

AU - Conter, V

AU - Biondi, A

AU - Colombini, A

AU - Micalizzi, C

AU - Zecca, M

AU - Parasole, R

AU - Petruzziello, F

AU - Basso, G

AU - Putti, M C

AU - Locatelli, null

AU - d'Adamo, P

AU - Valsecchi, M G

AU - Decorti, G

AU - Rabusin, M

PY - 2017/1

Y1 - 2017/1

N2 - Drug-related toxicities represent an important clinical concern in chemotherapy, genetic variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was performed on 508 pediatric acute lymphoblastic leukemia patients treated with AIEOP-BFM 2000 protocol: 28 variants were genotyped by VeraCode and Taqman technologies, deletions of GST-M1 and GST-T1 by multiplex PCR. Toxicities were derived from a central database: 251 patients (49.4%) experienced at least one gastrointestinal (GI) or hepatic (HEP) or neurological (NEU) grade III/IV episode during the remission induction phase: GI occurred in 63 patients (12.4%); HEP in 204 (40.2%) and NEU in 44 (8.7%). Logistic regression model adjusted for sex, risk and treatment phase revealed that ITPA rs1127354 homozygous mutated patients showed an increased risk of severe GI and NEU. ABCC1 rs246240 and ADORA2A rs2236624 homozygous mutated genotypes were associated to NEU and HEP, respectively. These three variants could be putative predictive markers for chemotherapy-related toxicities in AIEOP-BFM protocols.

AB - Drug-related toxicities represent an important clinical concern in chemotherapy, genetic variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was performed on 508 pediatric acute lymphoblastic leukemia patients treated with AIEOP-BFM 2000 protocol: 28 variants were genotyped by VeraCode and Taqman technologies, deletions of GST-M1 and GST-T1 by multiplex PCR. Toxicities were derived from a central database: 251 patients (49.4%) experienced at least one gastrointestinal (GI) or hepatic (HEP) or neurological (NEU) grade III/IV episode during the remission induction phase: GI occurred in 63 patients (12.4%); HEP in 204 (40.2%) and NEU in 44 (8.7%). Logistic regression model adjusted for sex, risk and treatment phase revealed that ITPA rs1127354 homozygous mutated patients showed an increased risk of severe GI and NEU. ABCC1 rs246240 and ADORA2A rs2236624 homozygous mutated genotypes were associated to NEU and HEP, respectively. These three variants could be putative predictive markers for chemotherapy-related toxicities in AIEOP-BFM protocols.

KW - Adolescent

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Chemical and Drug Induced Liver Injury

KW - Child

KW - Child, Preschool

KW - Clinical Trials as Topic

KW - Consolidation Chemotherapy

KW - Female

KW - Gastrointestinal Diseases

KW - Gene Deletion

KW - Genetic Predisposition to Disease

KW - Glutathione Transferase

KW - Humans

KW - Induction Chemotherapy

KW - Infant

KW - Logistic Models

KW - Male

KW - Multidrug Resistance-Associated Proteins

KW - Multiplex Polymerase Chain Reaction

KW - Mutation

KW - Nervous System Diseases

KW - Pharmacogenetics

KW - Pharmacogenomic Testing

KW - Pharmacogenomic Variants

KW - Phenotype

KW - Polymorphism, Single Nucleotide

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Predictive Value of Tests

KW - Pyrophosphatases

KW - Receptor, Adenosine A2A

KW - Retrospective Studies

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

KW - Journal Article

U2 - 10.1038/tpj.2015.83

DO - 10.1038/tpj.2015.83

M3 - Article

VL - 17

SP - 4

EP - 10

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 1

ER -